POLATUZUMAB-VEDOTIN+BENDAMUSTIN+RITUKSIMAB KAO TERAPIJA ZA SPAŠAVANJE I PREMOŠTAVANJE U RELAPSOVANOM/REFRAKTORNOM DIFFUZNOM LIMFOMU VELIKIH B-ĆELIJA – PREZENTACIJA I PREGLED SLUČAJA LITERATURA
Sažetak
Uvod: Difuzni B krupnoćelijski limfom (DLBCL) predstavlja paradigmu visoko kurativne bolesti sa stopom kompletnih remisija (CR) od ≈ 60%–70% u indukciji, preostalih 30%–40% pacijenata ima relaps/refraktornu bolest. Ova populacija pacijenata je veoma kritična i namenjena je pristupu tretmanu spasavanja. Novi pristupi i agensi mogu prevazići problem u 20%–25%. Što se tiče ovog problema, polatuzumab vedotin predstavlja jednu od opcija. Upotreba ovog agensa kao mosta za dalju konsolidaciju uvedena je iz realnog klinčkog iskustva sa ohrabrujućim rezultatima.
Prikaz slučaja: Predstavljamo 54-godišnjeg pacijenta sa dijagnozom primarnog gastričnog R/R DLBCL koji je uspešno lečen uvođenjem konjugata antitela polatuzumab vedotina. Pacijent je dodatno konsolidovan autolognim graftom.
Zaključak: S obzirom na nedostatak dostupnosti ćelijskih terapija u zemljama u razvoju, konjugat antitelo-lek može biti prihvatljiv pristup.
Reference
2. Crump M, Neelapu SS, Faroq U, et al. Outcome in refractory diffuse large B–cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017; 130 (16): 1800-8.
3. Petković I. Current trends in the treatment of primary mediastinal large B-cell lymphoma - an overview. Contemp Oncol (Pozn). 2015;19(6):428-35.
4. Gisselbrect C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28(27):4184-90.
5. Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 2022;386(7):640-54.
6. Varma G, Goldstein J, Advani RH. Novel agents in relapsed/refractory diffuse large B-cell lymphoma. Hematol Oncol 2023;41(suppl 1): 92-106.
7. Liebers N, Duell J, Fitzgerald D, et al. Polatuzumab vedotin as a salvage and bridging treatment in relapsed and refractory large B-cell lymphomas. Blood Adv 2021;5(13):2707-16.
8. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020;38(2):155-6.
9. Palanca-Wessels MC, Czuczman M, Salles G, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015; 16(6): 704-715.
10. Morschhauser F, Flinn IW, Advani R, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019; 6(5): e254-e265.
11. Phillips T, Brunvand M, Chen A, et al. Polatuzumab vedotin combined with obinutuzumab for patients with relapsed or refractory non-Hodgkin lymphoma: preliminary safety and clinical activity of a phase Ib/II study. Blood. 2016; 128(22):622.
12. Smith SD, Lopedote P, Samara Y, et al. Polatuzumab vedotin for relapsed/refractory aggressive B-cell lymphoma: a multicenter post-marketing analysis. Clin Lymphoma, Myeloma Leukemia. 2021; 21(3): 170-175.
13. Segman Y, Ribakovsky E, Avigdor A, et al. Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience. Leukemia & Lymphoma. 2021/01/02 2021; 62(1): 118-124.
14. Liebers N, Duell J, Fitzgerald D, et al. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. Blood Advances. 2021; 5(13): 2707-2716.
15. Northend M, Wilson W, Osborne W, et al. Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL. Blood Advances. 2022; 6(9): 2920-2926.
16. Vodicka P, Benesova K, Janikova A, et al. Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world. Eur J Haematol. 2022; 109(2):165.
17. Dimou M, Papageorgiou SG, Stavroyianni N, et al. Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas. Hematol Oncol. 2021; 39(3): 336-348.
